Nanotransfer

Nanomedicine / Gene Delivery Technologynanotransfer.bio

Nanotransfer is a Sunnyvale-based early-stage biotechnology company founded in 2021 that develops nanotechnology-based gene delivery systems. With 1-10 employees and minimal disclosed seed funding, the company operates at a pre-clinical research stage with no commercial products or revenue.

Company typePrivate
Founded2021
HeadquartersSunnyvale, United States
Headcount1–10
GTM typeB2B
OfferingServices

Nanotransfer firmographics

Firmographics

Name: Nanotransfer
Website: https://nanotransfer.bio
Company type: Private
Founded year: 2021
Operating status: Operating
Headcount range: 1–10 employees
Short description: Nanotransfer is a Sunnyvale-based early-stage biotechnology company founded in 2021 that develops nanotechnology-based gene delivery systems. With 1-10 employees and minimal disclosed seed funding, the company operates at a pre-clinical research stage with no commercial products or revenue.
Ownership category
akta.pro rank

Nanotransfer industry classification

Industry

Product category: Nanomedicine / Gene Delivery Technology
NAICS: Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in Nanotechnology (541713)
SIC: Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry: PRIMARYHLAAACAC
Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

Gene delivery systems
Nanotechnology platforms
Drug delivery
Biotech therapeutics
Genetic engineering

Where Nanotransfer is headquartered

Location

Headquarters

HQ city: Sunnyvale
HQ country: United States
HQ region: North America

Markets served

Nanotransfer business model

Business model

GTM type: B2B
Offering type: Services
Cost components: Personnel, Technology or R&D, Operations, Marketing or Sales

Nanotransfer product offering

Product offering

Core offering

Nanotransfer develops gene delivery systems based on nanotechnology. The company focuses on engineering nanoscale carriers and platforms to transport genetic material into target cells for therapeutic and research applications. As a small early-stage biotechnology firm, it operates out of Sunnyvale, United States.

Differentiator

Problem solved

Functional benefit

Products and services

Gene Delivery Systems Nanotechnology-based delivery platforms designed to transport genetic material into target cells for therapeutic and research applications. Targeted at biopharmaceutical and gene therapy research organizations needing advanced delivery vehicles.

Companies that use Nanotransfer

Customer profile

Ideal customer profiles1 record

Nanotransfer technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Nanotransfer competitors and assessment

Company assessment

Direct peers

Precision NanoSystems (Cytiva): Provides microfluidic-based nanoparticle formulation instruments and LNP development services for nucleic-acid delivery. Direct peer as a delivery-enabling platform serving the same customer base of nucleic-acid developers.
Acuitas Therapeutics: Specialist developer of lipid nanoparticle delivery systems for nucleic-acid therapeutics and vaccines. Most directly comparable peer to Nanotransfer because it is a pure-play, non-viral delivery platform with similar technology positioning.
Genevant Sciences: LNP and ligand-based nucleic-acid delivery platform that licenses its technology to therapeutic developers. Direct peer due to overlapping non-viral delivery focus and platform-licensing business model.
Arcturus Therapeutics: Develops RNA medicines including LNP-enabled mRNA and siRNA candidates. Direct peer because it integrates proprietary non-viral delivery chemistry with therapeutic programs in overlapping indications.
Arbutus Biopharma: Holds foundational LNP and GalNAc conjugate delivery IP for hepatitis B and other indications. Direct peer because it monetizes proprietary lipid and conjugate delivery chemistry — exactly the niche Nanotransfer is targeting.

Broad incumbents

BioNTech: Integrated mRNA therapeutics company with in-house LNP capabilities developed through its COVID-19 vaccine work. Broad incumbent because it competes for delivery-enabled nucleic-acid partnerships but operates across a much wider therapeutic portfolio.
Moderna: Operates proprietary LNP delivery alongside a broad mRNA pipeline. Broad incumbent: comparable delivery technology and target applications, but at vastly greater scale and with vertically integrated therapeutic development.

Emerging players

Intellia Therapeutics: In vivo CRISPR/Cas9 gene-editing company that is a downstream consumer of non-viral delivery technology. Emerging player overlap: a key potential customer/licensing partner for any third-party delivery platform like Nanotransfer.
Verve Therapeutics: In vivo base-editing company whose cardiovascular programs rely on LNP delivery of base editors. Emerging player: same delivery-technology dependency and similar early-stage platform profile.
Beam Therapeutics: Base-editing company using LNP and electroporation non-viral delivery for in vivo and ex vivo programs. Emerging player with overlapping interest in next-generation, non-immunogenic delivery systems for nucleic-acid cargo.

Market position

Customer concentration

Nanotransfer financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nanotransfer leadership team

Management profile

Number of profiles

Nanotransfer funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nanotransfer M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanotransfer

What does Nanotransfer do?

When was Nanotransfer founded?

Nanotransfer was founded in 2021. It employs 1 to 10 people.

Where is Nanotransfer based?

Nanotransfer is headquartered in Sunnyvale, United States, in the North America region.

Who are Nanotransfer's main competitors?

Direct peers on record are Precision NanoSystems (Cytiva), Acuitas Therapeutics, Genevant Sciences, Arcturus Therapeutics and Arbutus Biopharma. Broad incumbents are BioNTech and Moderna. Emerging players are Intellia Therapeutics, Verve Therapeutics and Beam Therapeutics.

Does Nanotransfer have an API?

No public API is recorded for Nanotransfer.

What industry is Nanotransfer in?

Nanotransfer's product category is Nanomedicine / Gene Delivery Technology. Its primary akta.pro industry code is HLAAACAC, Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods), with a secondary code of HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes). Its NAICS code is 541714 and its SIC code is 2836.